ArticleCureus2025
A Clot and a Clue: When Pulmonary Embolism Leads to a Renal Diagnosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary membranous nephropathy (PMN) is one of the leading causes of nephrotic syndrome (NS) in non-diabetic adults, potentially progressing to end-stage renal disease. The detection of specific antibodies, such as anti-phospholipase A2 receptor (anti-PLA2R), is useful for diagnosis, risk stratification, and monitoring therapeutic response. Clinical presentation is usually insidious, with edema, malaise, fatigue, and anorexia, but may be complicated by NS complications as thrombotic events. We present the case of a 45-year-old man with bilateral pleuritic chest pain and hemoptoic cough for the past week, and peripheral edema over six months. Contrast-enhanced chest computed tomography (CT) revealed bilateral pulmonary embolism (PE). Laboratory tests highlighted hypoalbuminemia (2.4 g/dL), nephrotic-range proteinuria (12 g/24h) with preserved renal function, and positive anti-PLA2R antibodies (80 RU/mL). Secondary membranous nephropathy was excluded and renal biopsy was deferred. Treatment with rituximab was initiated, resulting in analytical improvement and disappearance of anti-PLA2R antibodies at six months. Close monitoring of renal function and early initiation of conservative treatment are essential to prevent disease progression and complications of NS, with immunosuppressive therapy potentially required in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.